Our current data suggest that boosting intratumoral anti-tumor effector signals, such as CCL5, or blocking pro-inflammatory signals such as GM-CSF and IL-6, could serve as therapeutic options in combination with ICB, particularly in patients with combined obesity and RCC. This evidence concerns the gene CSF2 and neoplasm.